Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
17 Leser
Artikel bewerten:
(0)

Global Closed Drug Transfer Systems, 2022: Impact of Drug Toxicity and Safety Factors on Therapeutic Oncology Market Segments, Market Dynamics and Market Demographics - Research and Markets

DUBLIN, Dec 21, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Closed Drug Transfer Systems to 2022" report to their offering.

The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers.

Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues. Studies of nurses who work with cytotoxic drugs on a regular basis have found a statistically higher rate of spontaneous abortion. Several companies are responding to this unmet need by commercializing devices for closed transfer of these drugs. As the market evolves and user acceptance increases, so too will the impact of these products on oncology therapy protocols and drug delivery

Highlights

- Analyzes the impact of drug toxicity and safety factors on therapeutic oncology market segments, market dynamics and market demographics

- Provides detailed analysis of closed drug transfer products for the handing of cytotoxic drugs

- Analyzes demand drivers and competitive factors influencing closed drug transfer adoption

- Charts product data and provides forecasts to 2022

- Profiles closed drug transfer device participants, their product development activities, business strategies, and corporate alliances and affiliations

Key Topics Covered:

1. Executive Summary

2. Cytotoxic Drug Therapeutics Market Dynamics

- Therapeutic Trends and Issues

- The Administration of injectable/Infusible Antineoplastics

- Drug Packaging and Administration Technology

- Closed Drug Transfer Market Drivers

- Competitive Landscape

- Risk Factors

3. Closed Drug Transfer Design Factors

- Key System Design Elements

- Human Engineering/Ergonomics

- Material Selection Issues

- Drug Reconstitution and Dilution

- Oncology Therapeutics Medication Safety

- Oncology Drug Administration and Dosing

- Drug-Specific Dosing Modification and Individualized Dosing

4. Closed Drug Transfer - Commercial Device Assessments

5. Market Factors

6. Regulatory Issues

- Caregiver Compliance

- Level of Complexity and Ease of Use

- Healthcare Economics

- Business Models and Strategies

7. Market Assessments and Forecasts

8. North America

- Europe

- Asia

- Other Geographic Markets

9.Closed Drug Transfer - Market Participant Profiles

For more information about this report visit http://www.researchandmarkets.com/research/292jq3/closed_drug

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.